1. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Winchester DP (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. Cancer J Clin 67(2):93–99
2. Pessôa Pereira D, Mateus Fernandes SM, Mendonça Sampaio LV, Custódio SJ, Lima Oliveira CT, Campos SI, Luciano Espinheira F, José Lobão SL, Rogério Alves LC, Helton Estrela R (2019) Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series. Arch Endocrinol Metabol 63(2):97–106
3. Curado M-P, Edwards B, Shin HR et al (2007) Cancer incidence in five continents, vol 4. IARC Press, International Agency for Research on Cancer, Lyon
4. Espenbetova M, Amrenova K, Zhumanbayeva Z, Zamanbekova Z, Yurkovskaya O, Shalgumbayeva G, Dyussupova A, Telford O, Glushkova N (2018) Effectiveness of percutaneous ethanol injection in nodular diseases of the thyroid gland: 10-year follow-up. Endoc Prac 24(11):982–987. https://doi.org/10.4158/EP-2018-0215
5. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F (2008) BRAF (V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study. J Clin Endocrinol Metab 93:3943–3949